Alpha 2.0
Login Register
» Articles » PMID: 21490784

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Overview
Journal AIDS Res Treat
Publisher Wiley
Specialty Infectious Diseases
Date 2011 Apr 15
PMID 21490784
Citations 49
Authors
Carole L Wallis
John W Mellors
Willem D F Venter
Ian Sanne
Wendy Stevens
Affiliations
Soon will be listed here.
Abstract

Limited data exist on HIV-1 drug resistance patterns in South Africa following second-line protease-inhibitor containing regimen failure. This study examined drug resistance patterns emerging in 75 HIV-1 infected adults experiencing virologic failure on a second-line regimen containing 2 NRTI and lopinavir/ritonavir. Ninety six percent of patients (n = 72) were infected with HIV-1 subtype C, two patients were infected with HIV-1 subtype D and one with HIV-1 subtype A1. Thirty nine percent (n = 29) of patients had no resistance mutations in protease or reverse transcriptase suggesting that medication non-adherence was a major factor contributing to failure. Major lopinavir resistance mutations were infrequent (5 of 75; 7%), indicating that drug resistance is not the main barrier to future viral suppression.

Citing Articles

Viral Suppression and HIV Drug Resistance Among Patients on Second-Line Antiretroviral Therapy in Selected Health Facility in Ethiopia.

Zealiyas K, Gebreegziabxier A, Getaneh Y, Kidane E, Woldesemayat B, Yizengaw A Viruses. 2025; 17(2).

PMID: 40006960 PMC: 11860432. DOI: 10.3390/v17020206.

Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART.

Zhao Y, Voget J, Singini I, Omar Z, Mudaly V, Boulle A South Afr J HIV Med. 2024; 25(1):1567.

PMID: 38725705 PMC: 11079356. DOI: 10.4102/sajhivmed.v25i1.1567.

Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.

Jennings L, Kellermann T, Spinelli M, Nkantsu Z, Cogill D, Van Schalkwyk M AIDS Res Hum Retroviruses. 2021; 38(6):455-462.

PMID: 34779228 PMC: 9225825. DOI: 10.1089/AID.2021.0135.

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.

Obasa A, Ambikan A, Gupta S, Neogi U, Jacobs G BMC Infect Dis. 2021; 21(1):214.

PMID: 33632139 PMC: 7908688. DOI: 10.1186/s12879-021-05905-2.

A retrospective descriptive investigation of adult patients receiving third-line antiretroviral therapy in the North West province, South Africa.

Rudman C, Viljoen M, Rheeders M Afr Health Sci. 2020; 20(2):549-559.

PMID: 33163016 PMC: 7609084. DOI: 10.4314/ahs.v20i2.2.

References
1.
Pulido F, Perez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J . Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009; 14(2):195-201. DOI: 10.1177/135965350901400210. View
2.
Soares E, Santos A, Sousa T, Sprinz E, Martinez A, Silveira J . Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One. 2007; 2(8):e730. PMC: 1939879. DOI: 10.1371/journal.pone.0000730. View
3.
Kantor R, Katzenstein D . Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003; 5(1):25-35. View
4.
Banke S, Lillemark M, Gerstoft J, Obel N, Jorgensen L . Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol. 2009; 83(17):8916-24. PMC: 2738184. DOI: 10.1128/JVI.00003-09. View
5.
Venhoff N, Setzer B, Melkaoui K, Walker U . Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther. 2007; 12(7):1075-85. View